GLPwatch
A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity
NCT07767175 · Recruiting
Last updated 2026-09-22This study is testing the safety of a new investigational drug called NNC0721-8060 in adults who are overweight or have obesity.
Status Recruiting Currently enrolling participants.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, double-blind treatment study
Participants 142 people Planned (estimated).
Who can join Ages 18–55 · all sexes Healthy volunteers accepted.
Timeline Started 2026-08 · est. completion 2027-09
Where 2 sites · United States
What this study is testing ClinicalTrials.gov NCT07767175 ↗
Description as written by the study sponsor.
The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.
Treatments tested
- NNC0721-8060 Drug
NNC0721-8060 will be administered subcutaneously.
- Semaglutide Drug
Semaglutide will be administered subcutaneously.
- Placebo Drug
Placebo will be administered subcutaneously.
| Main thing measured | Part A: Number of treatment emergent adverse events (TEAE) |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Conditions studied | Overweight, Obesity |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07767175 ↗